About US
Contact us
-
UK spending on new medicines is fallingThe NHS in England is spending increasingly less on innovative new medicines, an industry expert has revealed. A recent report from OHE Consulting, compiled on behalf of the Association of the Britis2012/11/5
-
Report recommends patient-centric approach to encourage adherenceMany patients fail to adhere to their treatment regimes, losing national health care industries billions of pounds every year. A new report by Cutting Edge Information claims that one of the best way2012/11/5
-
Visterra to present efficacy data on VIS410 against H5N1 influenzaVisterra has announced that it will be presenting prophylactic and therapeutic efficacy data for VIS410 in the treatment of the H5N1 (Avian Flu) strain of influenza at a conference in Vietnam. The co2012/11/2
-
Shionogi to take 10pc stake in GSK HIV drugJapanese pharmaceutical group Shionogi is to receive a ten per cent stake in ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK) and Pfizer. Under the terms of the deal, ViiV will acquire2012/11/2
-
Bayer set to buy Schiff Nutrition International for $1.2bnGerman drugmaker Bayer has agreed to buy Schiff Nutrition International for approximately US$1.2 billion, the company has confirmed. Schiff is a leading vitamin manufacturer in the US, with its portf2012/11/1
-
More Sharing ServicesShare: Share on facebookShare on twitterShare on linkedinShare on sinaweiboShare on baiduShare on emailShare on printWatson sells Rugby OTC products and trademarks to Major PharmaceuticalsWatson Pharmaceuticals has sold its Rugby over-the-counter (OTC) pharmaceutical products and trademarks to Major Pharmaceuticals, a division of the Harvard Drug Group. The transaction was valued at a2012/11/1
-
Bayer set to buy Schiff Nutrition International for $1.2bnGerman drugmaker Bayer has agreed to buy Schiff Nutrition International for approximately US$1.2 billion, the company has confirmed. Schiff is a leading vitamin manufacturer in the US, with its portf2012/10/31
-
Sanofi to continue developing Prednisporin under sub-licencing agreementSanofi has announced in its latest quarterly financial update that the company intends to continue developing Prednisporin under the terms of a sublicense agreement with a third party. Prednisporin i2012/10/31
-
Organisational structure 'key to pharma compliance'With only a quarter of leading pharmaceutical companies having centralised their compliance departments, new research suggests that organisational structure is crucial to improving these efforts. Acc2012/10/30
-
'Slight decline' in pharmaceutical M&A activityThe last 18 months has seen a slight decline in pharmaceutical merger and acquisition (M&A) activity, following steady levels since 2008, a report has revealed.Research by intelligence firm Irving2012/10/30